Dianthus (DNTH) Therapeutics announced completion of enrollment in the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis. DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein. Initial top-line results from the MaGic trial are anticipated in September 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge
- Short Report: Bears focus on crypto space, boost bets on CleanSpark, Mara
- Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress
- Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating
- Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue